PSNL News and Press, Personalis Inc. From 04/12/22

Tool detects increasingly important biomarker for immunotherapy Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, " A machine learning algorithm with subclonal sensitivity reveals wid...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal . The patent, US Patent No. 11,299,783, entitled “Met...

Profiling feasibility study uses a combined transcriptome and exome approach to confirm and augment upon previous molecular subtyping method in colorectal cancer Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorshi...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21 st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time. About Personalis Personalis,...

Personalis’ oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing revenue from pharmaceutical companies Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today an...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 , which will be held in-person and online, April 8-13, 2022. ...

Personalis, Inc. (PSNL) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Kevin D...

Personalis press release (NASDAQ:PSNL): Q4 GAAP EPS of -$0.45 beats by $0.05. Revenue of $20.68M (+2.5% Y/Y) in-line. Full year 2022 Outlook Total company revenue is expected to be approximately $67.0 million vs. $66.22M consensus Revenue from biopharma and all other customers, excluding the ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Recent Highlights Reported quarterly revenue of $20.7 million in the fou...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. Eastern Time. About Personalis Personalis, Inc. is a le...